- Home
- ASA vs XOMA Comparison
ASA vs XOMA Comparison
Compare ASA & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASA
- XOMA
- Stock Information
- Founded
- ASA 1958
- XOMA 1981
- Country
- ASA United States
- XOMA United States
- Employees
- ASA N/A
- XOMA N/A
- Industry
- ASA Precious Metals
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- ASA Industrials
- XOMA Health Care
- Exchange
- ASA Nasdaq
- XOMA Nasdaq
- Market Cap
- ASA 415.9M
- XOMA 355.6M
- IPO Year
- ASA N/A
- XOMA N/A
- Fundamental
- Price
- ASA $21.95
- XOMA $26.98
- Analyst Decision
- ASA
- XOMA Strong Buy
- Analyst Count
- ASA 0
- XOMA 2
- Target Price
- ASA N/A
- XOMA $81.50
- AVG Volume (30 Days)
- ASA 60.6K
- XOMA 35.1K
- Earning Date
- ASA 02-04-2025
- XOMA 03-07-2025
- Dividend Yield
- ASA 0.18%
- XOMA N/A
- EPS Growth
- ASA 302.95
- XOMA N/A
- EPS
- ASA 4.56
- XOMA N/A
- Revenue
- ASA $1,993,559.00
- XOMA $21,606,000.00
- Revenue This Year
- ASA N/A
- XOMA $511.48
- Revenue Next Year
- ASA N/A
- XOMA $26.91
- P/E Ratio
- ASA $4.78
- XOMA N/A
- Revenue Growth
- ASA N/A
- XOMA 389.82
- 52 Week Low
- ASA $13.18
- XOMA $18.95
- 52 Week High
- ASA $22.78
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- ASA 65.96
- XOMA 48.76
- Support Level
- ASA $21.57
- XOMA $26.02
- Resistance Level
- ASA $22.33
- XOMA $29.02
- Average True Range (ATR)
- ASA 0.48
- XOMA 1.23
- MACD
- ASA 0.11
- XOMA 0.27
- Stochastic Oscillator
- ASA 79.76
- XOMA 60.31
About ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.